LimeLight of The week is

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H)

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

Investment Considerations

• Developing Nature Identical™ peptides derived from Caribbean Blue Scorpion venom to treat, regulate and prevent cancer progression
• Global market for cancer treatments projected to reach $161.3 billion by 2021
• Unique Sol-gel nose-to-brain CBD delivery platform under development to provide clinical relief of various physical disorders
• Global neuropathic pain market estimated at $8.3 billion by 2024
• Proof of concept already demonstrated for dual-gene therapy for type 2 diabetes and obesity
• Global expenditure for diabetes market in 2016 reached $825 billion

Receive Text Alerts from CannabisNewsWire

Text "Cannabis" to 21000

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.